Biopharmaceutical company Lipocine has announced positive Phase I study results for novel once-a-day oral testosterone, LPCN 1111.

The novel prodrug of testosterone, LPCN 1111, leverages the company’s Lip’ral technology to enhance solubility and improve absorption during testosterone replacement therapy.

"The novel prodrug of testosterone, LPCN 1111, leverages the company’s Lip’ral technology to enhance solubility and improve absorption during testosterone replacement therapy."

Lipocine chief technology officer Dr Srinivasan Venkateshwaran said; "We are very pleased to report that data from the Phase I trial indicate that LPCN 1111 appears to be the first once-a-day, orally-active testosterone replacement therapy ever advanced into the clinic."

According to the study data, LPCN 1111 demonstrated a good safety profile and pharmacokinetic prolife, supporting once-a-day dosing of the next-generation oral testosterone replacement product.

The LPCN 1111 development programme adds to Lipocine’s line of potential products, which include a twice-daily oral testosterone replacement, LPCN 1021, that is currently entering Phase III clinical trials.

Lipocine president and CEO Dr Mahesh Patel said new oral testosterone dosage forms will make a major contribution to the expanding market for testosterone replacement therapy.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

"We believe a once-a-day product will be strongly differentiated and provide a significant advancement in this market. Based on these data, LPCN 1111 is poised to be the first such product in this class," Patel said.